Which Drugs Actually Prevent Chronic Migraines?

Are the newer migraine drugs really worth the hype?

Yes. A systematic review of 43 randomized trials covering 14,725 adults with chronic migraine found that newer CGRP-targeted medications cut monthly migraine days by about two and were generally well tolerated. Older drugs like topiramate, valproate, propranolol, and botulinum toxin showed weaker, less consistent benefits and caused more people to quit treatment due to side effects.

Chronic migraine means having 15 or more headache days every month. That is not a bad headache. That is a life-disrupting condition that costs people their jobs, their sleep, and their relationships. For decades, the only options were medications borrowed from other conditions, like blood pressure pills, seizure drugs, and antidepressants. None of them were designed for migraine, and many came with rough side effects.

In the last few years, a new class of drugs has changed that. CGRP-targeted medications block a specific protein that drives migraine attacks. This meta-analysis is the first to grade all the major options head-to-head using the GRADE system, the gold standard for ranking the certainty of medical evidence.

What the data show

The researchers pooled results from 43 randomized controlled trials. With high- and moderate-certainty evidence, five CGRP drugs stood out: eptinezumab, erenumab, fremanezumab, galcanezumab, and atogepant. Each one reduced monthly migraine days by roughly two compared with placebo. That may sound modest, but for someone losing half the month to headaches, two extra clear days each month adds up to 24 days a year of life back.

Just as important, these newer drugs were well tolerated. People stayed on them. The older preventive medications, by contrast, had weaker and less consistent effects on migraine frequency. They also caused more side effects severe enough to make patients stop taking them.

Dr. Kumar’s Take

As a neurosurgeon, I do not manage chronic migraine day-to-day, but I sit on the receiving end of this story. I see patients referred for imaging or surgical workup whose lives have been quietly ruined by 15-plus headache days a month, often after years of borrowed medications like topiramate or propranolol that left them with brain fog, weight gain, or fatigue and only modest relief. Watching the CGRP class arrive has been one of the more encouraging shifts in neurologic medicine I have witnessed.

I also want to push back on the headline number, because the average of two fewer migraine days per month understates what actually happens in the clinic. The trials behind this class consistently report that 30 to 60 percent of patients are “50 percent responders,” meaning they cut their migraine days at least in half. A meaningful subset, often around 20 to 30 percent depending on the drug, are “super-responders” who see a 75 percent or greater reduction. And a smaller but real group, on the order of 5 to 20 percent in long-term extension studies, achieve near-complete remission for stretches of months or longer. The average of two days lumps these dramatic responders together with non-responders, which is exactly why averages are the wrong way to think about an individual decision.

The practical implication: if a CGRP drug is going to work well for you, you will usually know within two to three months. If it does not, switching to a different drug in the class is reasonable, because response to one CGRP agent does not predict response to another. Cost remains a real barrier, since these drugs are expensive and insurance often requires documented failure of older medications first.

How strong is the evidence?

The strength of this review comes from how it grades the evidence, not just how much evidence it includes. GRADE assessment looks at study design, consistency across trials, precision of the results, and risk of bias. The CGRP drugs earned high- and moderate-certainty ratings, meaning we can be confident the effect is real and the size is close to what trials show.

Older medications received lower certainty ratings. That does not mean they never work. It means the evidence supporting them is weaker, with more variation between trials and more concerns about how the studies were done. For patients and doctors making decisions, that distinction matters.

Who benefits most

This study focused specifically on adults with chronic migraine, meaning 15 or more headache days per month. The findings may not apply the same way to people with episodic migraine, which is fewer headache days. Patients who have already tried and failed older medications are particularly good candidates for CGRP drugs, since the trials included many people in exactly that situation.

Anyone considering a switch should talk with a neurologist or headache specialist who can match the right drug to the right patient. Some CGRP medications are pills taken daily, others are monthly injections, and one is an infusion given every three months. The choice depends on lifestyle, other health conditions, and insurance coverage.

Practical Takeaways

If you have 15 or more headache days per month and older medications have not helped, ask your doctor specifically about CGRP-targeted drugs like erenumab, fremanezumab, galcanezumab, eptinezumab, or atogepant.
Track your headache days in a simple diary for one to two months before starting any new medication, so you have a real baseline to measure improvement against.
Be realistic about expectations: a reduction of two migraine days per month is a meaningful result, not a cure, and finding the right drug may take some trial and error.
If cost is a barrier, ask about manufacturer patient assistance programs, since most CGRP drug makers offer reduced-cost or free options for qualifying patients.

FAQs

How long does it take for CGRP migraine drugs to start working?

Most people who respond to CGRP medications notice some improvement within the first month, and the full effect typically shows up by three months. If you have not seen any benefit after three months on a given drug, it is reasonable to discuss switching to a different CGRP option, since not every patient responds to every medication in the class. Some headache specialists recommend trying at least two different CGRP drugs before concluding that the class does not work for you.

Can I take a CGRP drug along with an older migraine medication?

Yes, and many headache specialists do combine them when one drug alone is not enough. There is no evidence that taking, for example, topiramate alongside a CGRP injection causes dangerous interactions, since the two drugs work through completely different pathways. Combination therapy is often used for patients with the most stubborn chronic migraine, though the meta-analysis itself looked at individual drugs rather than combinations.

Are CGRP drugs safe to take for years?

The CGRP class is still relatively new, with the first drugs approved in 2018, so we do not yet have decades of long-term safety data. What we do have is reassuring: trials and post-market surveillance show low rates of serious side effects through several years of continuous use. The most common complaints are mild injection-site reactions, constipation, and occasional cold-like symptoms. Patients with significant cardiovascular disease should discuss the trade-offs with their doctor, since CGRP plays some role in blood vessel function.

Bottom Line

For adults with chronic migraine who have lived through the disappointing era of borrowed medications, this is the clearest evidence yet that the newer CGRP-targeted drugs work better and are easier to tolerate than the older preventive options. A two-day-per-month reduction backed by high-certainty evidence is a real shift, not marketing hype. If you have not had this conversation with your doctor, it is worth having now.

Read the full study